Brian Arey - Part 2: GPCR Drug Discovery and the Science Nobody Publishes

Drug discovery in the pharmaceutical industry generates enormous volumes of foundational science that never reaches a journal. Target validation programs are built, defended, and sometimes cancelled before a single paper is submitted. The scientists who do this work accumulate expertise - in receptor signaling, cardiovascular physiology, mechanobiology - that exists in internal reports and institutional memory rather than the published record.

In this conversation, Arey traces the full arc of how a pharmaceutical research program is born, resourced, and either advanced or discontinued. He describes his work on GPCR mechanotransduction in endothelial cells - including the early identification of GPR56 as a mechanical sensor and his sustained case for the KLF2 signaling pathway as a GPCR-linked therapeutic target in atherosclerosis - and is candid about what happens when organizational priorities shift and a program you believe in gets shelved.

Arey's conviction that the KLF2-GPCR axis in vascular endothelium represents an underexplored route to treating atherosclerosis has not diminished with time. This episode is for scientists who want to understand what early drug discovery actually costs - and what it produces that the literature cannot capture.

About the Guest

Brian Arey is a pharmacologist and physiologist with over 25 years of pharmaceutical research experience at Bristol-Myers Squibb. His scientific work spans GPCR mechanotransduction in vascular endothelial cells, cardiovascular target validation, thrombosis pharmacology, and metabolic disease biology, with contributions to multiple clinical programs including preclinical models that supported the apixaban development program. He has led mechanistic pharmacology operations and served as interim head of a 70-person cross-functional research organization spanning mechanistic pharmacology, compound management, and core automation. His approach to drug discovery is grounded in classical physiology and driven by a willingness to enter fields - bone biology, thrombosis, endothelial function - with limited prior expertise and build toward the question the science is actually asking.

Scientific Themes of the Conversation

• The architecture of drug discovery: from pathophysiology to program governance
  

• GPCR mechanotransduction in endothelial cells: GPR56, KLF2, and atherosclerosis
  

• Hypothesis discipline and the "killer experiment" in early discovery
  

• Intellectual humility and the dynamics of cross-functional drug discovery teams
  

• Career breadth across physiology systems: scientific advantage and professional cost
  

• Scientific identity, intuition, and the scientist who refuses the mold

Key Insights from the Conversation

Early discovery is the most creative and most invisible space in pharmaceutical research

Arey describes early-stage drug discovery as structurally similar to academic research - hypothesis-driven, iterative, without guaranteed output. The difference is that the science is consumed by the organization rather than the literature. Scientists who build careers in this space often generate more foundational knowledge than their publication records reflect, and Arey is unusually candid about what that obscurity actually feels like from the inside.

The "killer experiment" is the one designed to end your own program

A mentor taught Arey the concept of the killer experiment: the definitive test engineered specifically to challenge your own hypothesis before more resources are committed. The discipline requires a willingness to invest in an outcome that might close what you have built. Arey calls this one of the most important and least instinctive skills in pharmaceutical research - and one that most scientists are never explicitly taught.

GPR56 as a GPCR mechanosensor in endothelial cells - a decade ahead of the published literature

Working on endothelial cell responses to shear stress, Arey identified GPR56 as a candidate mechanosensor before the concept had been established in print. A paper confirming the receptor's mechanotransduction function in endothelial cells appeared roughly ten years later. He describes the experience with something between resignation and dry satisfaction: he knew, the data supported it, and the field eventually arrived.

The KLF2-GPCR axis in atherosclerosis: a program that ended, a conviction that did not

Arey spent years building the case for GPCRs and the KLF2 transcription factor as a linked anti-inflammatory pathway in vascular disease. The program was eventually deprioritized as oncology absorbed industry attention. His belief in the biology has not changed. He says so directly: "somebody please do it" - not as a rhetorical gesture, but as a genuine ask to whoever is listening.

Breadth across physiology systems carries a professional cost that nobody warns you about

Moving between neuroscience, reproductive endocrinology, bone biology, thrombosis, and cardiovascular disease in one career generates a depth of cross-system physiological understanding that Arey considers genuinely valuable for drug discovery. He is equally honest that the approach slows career progression - each transition resets the publication clock and delays the depth of specialization that institutional advancement rewards. He made the trade knowingly, and would make it again.

In drug discovery, intuition precedes the hypothesis - not the other way around

Arey argues that the most significant hypotheses he has generated throughout his career originated in pattern recognition and intuition, before any supporting data existed. He is careful not to overstate this: data drives decisions. But he maintains that the hypothesis itself - the moment where you commit to a direction - comes from something that looks more like a gut feeling than a literature review. For scientists trained to distrust that instinct, it is a useful challenge.

Trust is not a leadership style - it is the operating condition for innovative science

Running a 70-person research organization, Arey returns repeatedly to trust as the variable that determines whether people bring their actual thinking to the team. Not warmth, not informality - but the concrete belief among scientists that their leader has their interests at heart. He describes this as the only environment in which people are willing to surface the unconventional idea that might be the one that works.

Episode Timeline

Timestamps are AI-generated from the transcript and may require minor manual adjustment.

• 01:30 - Returning to the conversation: leading a 70-person organization on an interim basis

• 03:10 - Leadership style: trust, communication, and creating the conditions for good science

• 08:58 - The drug discovery process from pathophysiology to target selection

• 16:49 - Organizational patience and the go/no-go discipline in early discovery

• 23:09 - GPR56 as a GPCR mechanosensor: knowing the answer before the field did

• 27:35 - Intellectual humility and the drug discovery team as a problem-solving unit

• 37:10 - The KLF2 pathway, GPCRs, and atherosclerosis: a program that ended too soon

• 42:39 - Career breadth across physiology: the advantage and the professional cost

• 57:50 - Scientific identity, introversion, and putting yourself out there

• 01:05:19 - Intuition as hypothesis generator: what comes before the data

Selected Quotes

About this episode

Brian Arey is Senior Director of Mechanistic Pharmacology within Leads Discovery and Optimization at Bristol-Myers Squibb Co. in Lawrenceville, NJ.

He obtained both his MS and Ph.D. in Neuroendocrine Physiology at Florida State University before completing his postdoctoral training at Northwestern University. He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility. He currently leads a team that provides a mechanistic understanding of small molecule drug candidates across the entire portfolio of BMS. Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular, biochemical, cellular, and in vivo assessment of drug candidates in many different physiological systems.

Dr. Arey’s laboratory discovered the first described synthetic agonists and antagonists of the FSHR and has been an early champion of signaling bias as a physiological mechanism of gonadotropin action. He continues to pioneer in drug discovery studying GPCRs and other target classes. His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics is available on Amazon.

I sat down with Brian to chat about GPCRs, working in the industry, and being a leader. This is part 1 of our conversation.

Dr. Brian Arey on the web

• LinkedIn

• ResearchGate

• Pubmed

• Dr. GPCR Ecosystem